Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 72

Results For "regulatory"

1432 News Found

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
News | August 09, 2023

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base


Brenntag partners with Qualifyze to enhance pharma audit offering
News | August 09, 2023

Brenntag partners with Qualifyze to enhance pharma audit offering

Qualifyze specializes in Good Practice audits (GxP) audits and covers a wide range of areas, including excipients, starting materials, packaging, sustainability


Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023
Policy | August 09, 2023

Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023

Several crucial provisions to elevate the standards of nursing education and services, enhance professional conduct, and ensure greater transparency and accountability introduced


Syrma SGS acquires majority sake in Johari Digital Healthcare
Digitisation | August 02, 2023

Syrma SGS acquires majority sake in Johari Digital Healthcare

JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices


Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries
News | August 01, 2023

Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries

The company has secured 506 marketing approvals for its oncology products across 76 countries.


Concord Biotech’s IPO to open on 4th August, 2023
News | August 01, 2023

Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.


Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Drug Approval | August 01, 2023

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy


Biogen to acquire Reata Pharmaceuticals
News | July 31, 2023

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth